Financial Performance
5Y price score: 140
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 199.7%
US$ Per
Share
By default your notes are visible only to you.
269.7
52-week range
447.0
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
4.2 %
Dividend Yield TTM
2.2 %
Market cap $
$ 238,681
Price / Earnings TTM
27.5
Price / Book TTM
20.4
PEG TTM
0.4
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
56.6 %
118.5 %
199.7 %
Free cash flow per share growth
81.6 %
(10.8) %
35.8 %
Earnings per share growth
64.9 %
15.6 %
57.1 %
Founded: 1,980
Employees: 28,000
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Aug 4, 2026)
1) Strategy & Leadership - Amgen's strong Q2 2026 results were driven by a diverse portfolio, demonstrating resilience against patent expirations and competition. - The company is confident in achieving durable growth through its six key growth drivers, which collectively grew at 26% YoY and accounted for nearly 70% of product sales. - Investments in innovation and technology, including AI, are central to advancing their pipeline and operational efficiency.
2) Financial & Segment Results - Total revenues exceeded $10 billion, marking a 10% increase YoY. - 22 products experienced double-digit sales growth, with 17 products annualizing over $1 billion in sales. - Key growth drivers included: - Repatha: $953 million in sales (+37% YoY) - EVENITY: $714 million in sales (+38% YoY) - TEZSPIRE: $486 million in sales (+42% YoY) - Rare Disease portfolio: $1.6 billion in sales (+21% YoY) - Innovative Oncology: Approximately $2 billion in sales (+18% YoY) - Biosimilars: $855 million in sales (+29% YoY)
| Metric | Q2 2026 Results | YoY Change |
|---|---|---|
| Total Revenues | $10 billion | +10% |
| Repatha Sales | $953 million | +37% |
| EVENITY Sales | $714 million | +38% |
| TEZSPIRE Sales | $486 million | +42% |
| Rare Disease Portfolio Sales | $1.6 billion | +21% |
| Innovative Oncology Sales | ~$2 billion | +18% |
| Biosimilars Sales | $855 million | +29% |
3) Problems / Headwinds - Prolia and XGEVA combined sales decreased by 33% YoY to $1.1 billion due to competition from biosimilars. - The company faces challenges in maintaining market share against new entrants in the PCSK9 inhibitor space, particularly with the recent approval of Merck's oral PCSK9.
4) Operational or Product Plans - Amgen is advancing its late-stage pipeline with key products like MariTide, Olpasiran, and Xaluritamig, focusing on addressing significant unmet medical needs. - The company is expanding the indications and geographic reach of its existing products while improving dosage administration and payer access. - Investments in manufacturing capacity are set to support the launch of MariTide and other growth drivers, with capital expenditures expected to be around $2.6 billion in 2026.
5) Guidance & Outlook / Investor Angle - Amgen raised its 2026 revenue guidance to a range of $38.2 billion to $39.4 billion, and non-GAAP earnings per share guidance to $22.30 to $23.50. - The company remains committed to returning capital to shareholders, with a 6% increase in dividends to $2.52 per share. - Overall, Amgen's strategic focus on innovation, operational efficiency, and market expansion positions it well for sustained growth.
Bottom line: Amgen's robust Q2 performance, driven by strong sales across key products and strategic investments in innovation, positions the company for durable growth and increased shareholder value in the coming years.
Annual Reports, Presentations And IR Contacts
Go to the websiteAmgen Inc. — Financial Overview, Stock Price, Market Cap
Amgen Inc. is a company. Founded in 1980. As of August 26, 2026, the company's market capitalization is $238680465920 with a current stock price of $442.24.